miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44

• Main Authors: Shang-Gin Wu (Author), Tzu-Hua Chang (Author), Meng-Feng Tsai (Author), Yi-Nan Liu (Author), Yen-Lin Huang (Author), Chia-Lang Hsu (Author), Han-Nian Jheng (Author), Jin-Yuan Shih (Author)
• Format: Book
• Published: Elsevier, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with EGFR activation or T790M resistance mutations; however, acquired resistance to osimertinib can still develop. This study explored novel miRNA-mRNA regulatory mechanisms that contribute to...